Markets MIST

Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development

July 11, 2025 — 02:50 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has initiated an underwritten public offering of its common shares, Series A and Series B warrants for purchasing common shares, and, for certain investors, pre-funded warrants in place of common shares.

All securities in this offering will be issued by Milestone. The offering's completion is subject to market conditions and other factors, with no guarantee regarding its timing, size, or terms.

The proceeds, alongside existing cash reserves, will fund the clinical development and commercial launch of etripamil for paroxysmal supraventricular tachycardia - PSVT, as well as support general corporate activities and working capital.

MIST currently trades at $1.715 or 32.9435% lower on the NasdaqGS.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
MIST

Latest Articles
Data is currently not available